Literature DB >> 3528049

Treatment of congenital immune deficiencies with a thymic hormone--thymic humoral factor.

Z T Handzel, Y Elitsur, S Algrimawi, S Moses, A Keynan, I Amitai, M Pecht, Y Burstein, V Buchner, N Trainin.   

Abstract

Five infants with congenital immune defects are presented. Three had various combined immune deficiencies (CID) and two had thymic deficiencies only. As bone marrow or thymus transplantations were not feasible in these patients, we attempted treatment with thymic humoral factor (THF), a thymic hormone, by daily i.m. injections during biweekly courses. In one CID patient, a partial improvement in immune indices and temporary clinical improvement were achieved. In the other two, THF did not arrest the patients' demise. The two patients with thymic dysplasia benefitted repeatedly from THF treatment, as exemplified by the disappearance of wasting, diarrhea and infections and by reconstitution of T cell parameters. Nevertheless, the patients relapsed after prolonged periods without THF administration. We therefore propose the administration of long-term, continuous or intermittent thymic hormone replacement therapy in infants with congenital thymic defects. Early diagnosis and immediate institution of treatment will probably improve prognosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3528049

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  2 in total

1.  The DiGeorge sequence. II. Immunologic findings in partial and complete forms of the disorder.

Authors:  W Müller; H H Peter; H C Kallfelz; A Franz; C H Rieger
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

2.  Effect of synthetic thymic humoral factor (THF-gamma 2) on T cell activities in immunodeficient ageing mice.

Authors:  C Goso; D Frasca; G Doria
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.